News
BioSpace: Odyssey to Aim $218 Million at Novel Targets
Mark Terry
Boston-based Odyssey Therapeutics completed an oversubscribed $218 million Series A round. The funds will be used to advance multiple programs from its pipeline and its discovery platform.